Sun Pharmaceuticals was set up in 1983 and the company started off with only 5

products to cure psychiatric illness. Sun Pharma is best known worldwide as the
manufacture of specialty Active Pharmaceuticals Ingredients and formulations.

However, the company is also concerned with chronic treatments such as

cardiology, psychiatry, neurology, gastroenterology, diabetology, and respiratory
ailments. Active Pharmaceuticals Ingredients (API) include peptides, steroids, hormones,
and anti-cancer drugs and their quality is internationally approved. The international
offices of Sun Pharmaceuticals Industries Ltd. are located in British Virgin Islands,
Russia, and Bangladesh. In India, the offices are in Vapi, Silvassa, Panoli, Ahmednagar,
and Chennai. Dilip S. Shanghvi is the Executive Chairman and managing Director of Sun
Pharma and Kamalesh H. Shah is the secretary.

There are 3 major group companies of Sun Pharmaceuticals Industries are:

• Caraco Pharmaceuticals Laboratories (based in Detroit, Michigan)

• Sun Pharmaceuticals Industries Inc. (Michigan)
• Sun Pharmaceuticals (Bangladesh)

In 1983, when Sun Pharma was set up, it only dealt with two cities in India ? West
Bengal and Bihar. In 1985, it started trading nationally and by 2000, Sun Pharmaceuticals
made its way through the international market. Products used in cardiology were
manufactured in 1987 and at that time, Monotrate was one of the first products that was
launched and went on to become a best-seller. In 1993, Sun Pharmaceuticals Industries
set up their own research institute and named it SPARC. SPARC became popular by
generating knowledge and honing process development skills across the world. In 1994,
Sun Pharma enrolled itself in the main stock exchanges in India. Subsequently in 1995,
the first API manufacturing plant was established at Panoli to mark its standard beyond
competition and also capture the international market.

Sun Pharmaceuticals shifted its headquarters in Mumbai as it is at the center of Indian

commercial trade. The company began its first international acquisition with an amount
of US$ 7.5 million, acquiring Caraco Pharm Lab in Detroit. After 8 acquisitions by 2000,
Sun Pharma established another research center at Mumbai with an objective to sharpen
skills for the US market. Later on, the company introduced a few more treatment areas
which include orthopedics, gynecology, and oncology.

Sun Pharma's speedy acclivity is one of its best attributes that has made it gain an
international status across the world. It is always updated with the latest data and is
highly competent. Quality remains the prime concern and is maintained strictly by the
team. There are 3 forms of medicines manufactured plied by the company: oral,
injectable, and delivery-system based. Caraco Pharm and the Halol Pharm Lab have got
the approval of UKMHRA and USFDA in recent years.

Sun Pharmaceuticals was one of the first pharmaceutical firms to file an application to
market a generic known as ANDA by assuring a 180-day marketing rights to formulate a
more usual version of anti-ulcer drug in the US market. Sun Pharma shared this
honorable 180-day achievement with Israel's Teva Pharmaceutical Industries. With such
achievements, Sun Pharmaceutical Industries Limited is still ruling the pharmaceutical
industry all across the world and is aiming high to gain popularity and success in brand
building by making newer discoveries everyday.

Sun Pharmaceuticals Corp is a private company categorized under Cosmetic Preparations

and located in Dover, DE. Our records show it was established in 1995 and incorporated
in Delaware. Register for free to see additional information such as annual revenue and
employment figures.

Location Type Single Location

Annual Sales (Estimated) Information not found
Employees (Estimated) 115
SIC Code View Details
NAICS Code 325620, Toilet Preparation Manufacturing
Products, Services and Brands Information not found
State of Incorporation Delaware
Years in Business 15

1983

Sun Pharma begins operations in Kolkata with 5 psychiatry - based products, first with 2
people and then with a 10 - employee team. Year 1 turnover - Rs. 1 million. Within a
year, the marketing effort is expanded to cover all eastern states. A compact
manufacturing facility for tablets/capsules is set up at Vapi.

1986

Administrative office is set up in Mumbai. Customer coverage extends to select cities in

Western India.

1987

Marketing operations are rolled out nation-wide.

1988
With the launch of the brands Monotrate and Angizem, the first few cardiology products
are launched. We feature for the first time in a market audit by the prescription tracking
company, ORG at rank 107th with 0.1% market share.

1989

The corporate office is shifted to Baroda, in the western state of Gujarat. Products used in
gastroenterology are introduced. Exports to neighbouring countries begin.

1991

Construction begins at the first research center SPARC (Sun Pharma Advanced Research
center), with 46,000 sq ft of research space, and investments of almost the size of that
year's profits. The company's turnover is Rs. 9.74 cr, and market rank is 70th.

1993

SPARC, the first research center, is inaugurated by His Excellency Shri K. R. Narayanan,
the Vice President of India. An office is begun in Moscow. Products are now registered
across 10 markets.

1994

After an IPO in October, we are listed on the major stock exchanges in India. The
offering is oversubscribed 55 times. A dosage form plant at Silvassa starts production.
Major expansion at the plant in Vapi is completed. For the first time, a brand from the
company, Monotrate, features among the top 250 pharma brands in the Indian market.
Experimenting with a focused marketing approach, a separate division, Synergy, is
carved out to market Psychiatry/ Neurology products.

Experimenting with a focused marketing approach, a separate division, Synergy, is

carved out to market Psychiatry/ Neurology products.

1995

Our first API plant at Panoli starts production.

A new division, Aztec, now renamed Azura, is begun for cardiology products, with a
further reallocation of products across divisions. Inca, a new division to market critical
care medication to intensive care units begins operations. International marketing is
strengthened with offices in Ukraine and Belarus.

1996
An API-manufacturing unit at Ahmednagar, the first of the our acquisitions, is bought
from Knoll Pharma. An equity stake is also picked up in Gujarat Lyka Organics Ltd., a
manufacturer of Cephalexin Active with a USFDA approval for the intermediate,
7ADCA. At the close of the year, we rank 27th with 2 products among the country's top
selling 300 pharma brands. Product registrations are now in place across 24 countries.

1997

We begin the first of our international acquisitions. As part of a technology-for-equity

agreement, a stake is acquired in a generic dosage form manufacturer; the Detroit-based
Caraco Pharm Labs. An equity stake is taken in MJ Pharma, a manufacturer of several
dosage form lines with UK MHRA approval for Cephalexin capsules.

TDPL, a company with an extensive product offering (oncology, fertility, anesthesiology,

pain management) is merged with Sun Pharma. Non profitable/small generic lines and
several smaller brands are dropped to rationalize the product mix. TDPL's products offer
a ready entry with known brands and customer equity into new high growth therapy areas
like oncology and gynecology. Marketing is reorganized once again, this time into 6
speciality-focused divisions. A research and development facility over 6,000 sq ft in
Mumbai, our second research site, is established. This center is equipped to make dosage
forms and create supporting technical documentation for the generic markets in North
America and Europe

1998

A basket of brands, which include several in the respiratory/asthma area, are acquired
from Natco Pharma. Our new formulation plant at Silvassa commences operations.

1999

Rank moves within the top 10 in the domestic market. For a quick entry in
ophthalmology, Milmet Labs is merged into Sun Pharma. The Cephalexin API
manufacturer Gujarat Lyka Organics is merged with Sun Pharma. 6 brands now feature
among the leading 300 prescription pharma brands in India.

2000

Ranked 5th among all companies in the domestic market on a monthly basis. Pradeep
Drug company, a Chennai based API manufacturer is merged with Sun Pharma.

Plans are shared to set up a new research campus in Chennai, which is later dropped as a
suitable site is found in Baroda where we have an existing base

2001
A new formulation plant is built in Dadra. This new plant is spread over a 5-acre site with
built up area of 120,000-sq. ft. and has been designed and built to comply with
international regulatory requirements, such as the UKMHRA and USFDA.

The erstwhile TDPL division is renamed Spectra. A new division, Arian, targeting
cardiologists/physicians and diabetologists, is launched.

2002

Forbes Global ranks Sun Pharma in the list of best small 200 companies for 2002
(turnover less than $500 million).

Sun Pharma is selected as the best company by Express Pharma Pulse, for overall
performance for 2002 (in the category A - market share over 2.5%).

4 manufacturing sites win the prestigious IDMA awards.

Work commences on a new, state-of-the-art drug discovery campus in Baroda; this 16-
acre site, with space for 400+ scientists on completion, will be commissioned over the
next two years.

Work begins on a new R&D center in Mumbai, with 50,000 sq. ft. floor area for projects
aimed at the North American and European markets.

2003

Forbes Global ranks Sun Pharma in the list of the best small 200 companies for 2003
(turnover less than $500million)

Sun Pharma is rated amongst the best-managed companies for 2003 across all sectors.
(Business Today-AT Kearney study of best-managed companies)

2004

Sun Pharma acquires common stock and options from 2 large shareholders of Caraco,
increasing stake to over 60% from 44% at a total outlay of about $42 million.

The formulation site in Halol, India (the erstwhile MJ Pharma site) receives approval
from USFDA, UK MHRA, South African MCC, Brazilian ANVISA and Columbian
INVIMA.

The BT Stern Stewart survey places Sun Pharma among the top 20 wealth creators in
India and among the top 3 wealth creators in the pharma sector.
Construction at a formulation manufacturing site at Jammu is completed.

Our first joint venture manufacturing unit, in Dhaka, Bangladesh is commissioned. This
modern site is spread over 25,000 sq. ft.

Two of Sun Pharma's API factories receive USFDA approval, taking the total number of
US FDA approved sites to three.

Sun Pharma acquires a Cephalosporin Actives manufacturer, Phlox Pharma, with

European approval for cefuroxime axetil amorphous.

Niche brands are bought from the San Diego, US based Women's First Healthcare.
(WFHC, not listed). These brands are the gynecological Ortho-Est� (estropipate), and
the antimigraine preparation Midrin�.

Forbes Global ranks Sun Pharma in the list of most valuable companies for 2004
(turnover less than $2bill).

2005

Sun Pharma buys a plant in Bryan, Ohio, US and the business of ICN, Hungary from
Valeant Pharma.

Sun Pharma acquires the intellectual property and assets of Able Labs from the US
District Bankruptcy court in New Jersey in December 2005.

Dilip Shanghvi, the CMD, receives the E&Y Entrepreneur of the Year award in
healthcare and life sciences for 2005.

Sun Pharma is selected by Forbes amongst the best 200 companies (sales less than USD 1
billion) in Asia. This is the fourth time in 5 years that the company has been selected.

2006

Announced the demerger of innovative business with pipelines, people, equipment and
funding, into a new company.

2007

Completed the demerger of the innovative business, with requisite legal and regulatory
approvals. SPARC ltd, the new company, is listed on the stock exchanges in India, the
first pure research company to be so listed.

In May 2007, we, along with our subsidiaries, signed definitive agreements to acquire
Taro Pharmaceutical Industries Ltd., (TAROF, Pink Sheets), a multinational generic
manufacturer with established subsidiaries, manufacturing and products across the U.S.,
Israel, Canada for $454 mill. This all-cash deal is subject to Taro shareholder approval
and requisite regulatory clearances

2008

Chattem Limited

In November 2008, we along with our subsidiaries, acquired 100% ownership of Chattem
Chemicals, Inc.,a narcotic raw material importer and manufacturer of controlled
substances with a approved facility in Tennessee. This will offer vertical integration for
our controlled substance dosage form business in the US.
(ORG - Operations Research Group Audit of Retail Chemist Sales, later renamed the
IMS - ORG Retail Store Audit. Both ORG and IMS are the trademarks of their registered
owners)